Glucose Consumption Accelerator for Diabetes Management

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for managing high glucose levels in diabetes, such as insulin injections and oral hypoglycemic drugs, are inadequate in effectively controlling glucose concentration, leading to complications like vascular damage.

Innovation Solution

A glucose consumption accelerator comprising compounds like 2-amino-1-cyclohexylethanol, 1-amino-2-propanol, and diethanolamine, which accelerate glucose uptake and glycolysis in cells, thereby reducing blood glucose levels.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If insulin injection or oral hypoglycemic drugs are used to control blood glucose level, then glucose concentration can be reduced, but the treatment effectiveness is insufficient and complications still occur

Engineering Contradiction:

Improveblood glucose levelVSAvoidtreatment effectiveness

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent changes the chemical parameter of the treatment agent by using Aramchol and its salts instead of conventional insulin or oral hypoglycemic drugs. This parameter change results in improved glucose consumption effectiveness and additional beneficial effects on lipid metabolism and inflammation, thereby resolving the contradiction between reducing glucose concentration and improving treatment reliability

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs a composite therapeutic approach where Aramchol acts as a multifunctional compound that simultaneously addresses glucose metabolism, lipid metabolism, and inflammation. This composite material strategy provides synergistic effects that improve overall treatment reliability beyond what single-agent therapies can achieve

Inventive Principle:

Principle #40Composite materials

2Quantity of substance

If conventional diabetes treatments are used, then some glucose control is achieved, but vascular damage and complications continue to progress

Engineering Contradiction:

Improveglucose concentrationVSAvoidvascular damage

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful effect of high glucose concentration into a beneficial therapeutic outcome by using Aramchol to actively promote glucose consumption and utilization. This transforms the pathological state of hyperglycemia into a therapeutic process where glucose is actively consumed and utilized, preventing vascular damage while managing glucose levels

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

Aramchol serves multiple functions simultaneously: it promotes glucose consumption, improves lipid metabolism, reduces inflammation, and prevents vascular damage. This multi-functionality addresses both glucose control and the prevention of harmful vascular complications, resolving the contradiction between achieving glucose control and preventing damage

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentEP3639818B1Glucose consumption promoter and glycolysis promoter

Publication Date: 2021.07.07 SHINKO SANGYO CO LTD

Figure 1A~1B
Figure 2A~2B
Figure 3A~3B

AI summary

The present invention provides a new drug that can accelerate glucose consumption. The glucose consumption accelerator of the present invention includes: at least one selected from the group consisting of 2-amino-1-cyclohexylethanol, 1-amino-2-propanol, 1,3-bis[tris(hydroxymethyl)methylamino]propane, N-cyclohexylethanolamine, diethanolamine, diethylamine, dipropylamine, morpholine, propylamine, triethanolamine, triethylamine, and trishydroxymethylaminomethane.